|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
Eloxx Pharmaceuticals
|
|
gptkbp:advocacy
|
support groups
|
|
gptkbp:allies
|
biotech companies
|
|
gptkbp:biopharmaceutical_development
|
therapeutic applications
|
|
gptkbp:biopharmaceutical_research
|
therapeutic development
|
|
gptkbp:biotech_advancements
|
scientific progress
|
|
gptkbp:biotech_community
|
collaborative efforts
|
|
gptkbp:biotech_ecosystem
|
collaborative networks
|
|
gptkbp:biotech_innovation
|
disruptive technologies
|
|
gptkbp:biotech_leadership
|
industry recognition
|
|
gptkbp:biotech_research
|
cutting-edge science
|
|
gptkbp:biotech_sector
|
innovative solutions
|
|
gptkbp:biotech_solutions
|
advanced treatments
|
|
gptkbp:business_model
|
partnerships
|
|
gptkbp:ceo
|
gptkb:André_Choulika
|
|
gptkbp:clinical_advancements
|
new methodologies
|
|
gptkbp:clinical_research_initiatives
|
therapeutic exploration
|
|
gptkbp:clinical_trial
|
ongoing
innovative therapies
advanced therapies
promising outcomes
robust evidence
Phase I/ II
|
|
gptkbp:collaboration
|
international partnerships
Servier Pharmaceuticals
|
|
gptkbp:collaborations
|
academic institutions
pharmaceutical companies
academic partnerships
leading institutions
|
|
gptkbp:community_engagement
|
health initiatives
|
|
gptkbp:focus
|
genome editing
|
|
gptkbp:founded
|
gptkb:1997
|
|
gptkbp:founder
|
gptkb:André_Choulika
|
|
gptkbp:funding
|
gptkb:venture_capital
|
|
gptkbp:global_presence
|
international markets
|
|
gptkbp:grants
|
funding opportunities
|
|
gptkbp:has_advisory_board
|
industry experts
|
|
gptkbp:headquarters
|
gptkb:Paris,_France
|
|
gptkbp:healthcare
|
advanced technologies
new treatments
transformative solutions
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cellectis Bioresearch
|
|
gptkbp:initiatives
|
innovative projects
|
|
gptkbp:innovation
|
gene editing technologies
|
|
gptkbp:instruction_set
|
multiple candidates
|
|
gptkbp:invention
|
gene editing methods
|
|
gptkbp:investment
|
biopharmaceuticals
shareholder engagement
|
|
gptkbp:is_a_platform_for
|
gene editing
|
|
gptkbp:leadership
|
expert researchers
|
|
gptkbp:location
|
gptkb:North_America
|
|
gptkbp:market
|
global
|
|
gptkbp:marketing_strategy
|
gptkb:expansion
|
|
gptkbp:mission
|
improving patient outcomes
|
|
gptkbp:notable_technology
|
novel therapies
|
|
gptkbp:number_of_employees
|
over 200
|
|
gptkbp:partnership
|
gptkb:Medi_Gene_AG
collaborative innovation
|
|
gptkbp:partnerships
|
strategic collaborations
|
|
gptkbp:patient-centered_approach
|
personalized therapies
|
|
gptkbp:product
|
gptkb:UCART19
cell therapies
|
|
gptkbp:publications
|
peer-reviewed journals
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
biotech regulations
|
|
gptkbp:research
|
cutting-edge technology
|
|
gptkbp:research_areas
|
gptkb:CAR_T-cell_therapy
oncology
personalized medicine
disease treatment
multiple indications
|
|
gptkbp:research_focus
|
genetic disorders
cellular therapies
hematological malignancies
|
|
gptkbp:side_effect
|
transforming treatments
|
|
gptkbp:social_responsibility
|
ethical practices
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:subsidiary
|
Cellectis Therapeutics
|
|
gptkbp:technology
|
TALENs
|
|
gptkbp:treatment
|
improved survival rates
|
|
gptkbp:vision
|
leading gene editing company
|
|
gptkbp:website
|
www.cellectis.com
|